Rituximab biosimilars: introduction into clinical practice

被引：2
|
作者：
Makita, Shinichi [1 ]
Tobinai, Kensei [1 ]
机构：
[1] Natl Canc Ctr, Dept Hematol, Chuo Ku, Tokyo 1040045, Japan
来源：
LANCET HAEMATOLOGY | 2017年 / 4卷 / 08期
关键词：
LYMPHOMA;
D O I：
10.1016/S2352-3026(17)30124-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E342 / E343
页数：2
相关论文
共 50 条
  • [21] Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America
    de la Cruz, Claudia
    de Carvalho, Andre V. E.
    Dorantes, Gladys L.
    Londono Garcia, Angela M.
    Gonzalez, Cesar
    Maskin, Matias
    Podoswa, Nancy
    Redfern, Jan S.
    Valenzuela, Fernando
    van der Walt, Joelle
    Romiti, Ricardo
    JOURNAL OF DERMATOLOGY, 2017, 44 (01): : 3 - 12
  • [22] Biosimilars in psoriasis: clinical practice and regulatory perspectives in Latin America
    De la Cruz, C.
    Carvalho, A.
    Leon-Dorantes, G.
    Londono Garcia, A.
    Gonzalez, C.
    Maskin, M.
    Podoswa, N.
    Redfern, J.
    Valenzuela, F.
    Van der Walt, J.
    Romiti, R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 98 - 98
  • [23] Knowledge of Biosimilars and Perceptions of Biosimilar Naming Conventions in Clinical Practice
    Lavery, Criswell
    Olave, Marianna
    Leonard, Charles
    Lo Re, Vincent
    Kay, Jonathan
    Baker, Joshua
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [24] Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration
    Mahmoudi, Hamidreza
    Tavakolpour, Soheil
    Balighi, Kamran
    Farid, Ali Salehi
    Nili, Ali
    Jan, Delnavaz
    Daneshpazhooh, Maryam
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [25] Rituximab biosimilars open new horizons in immunotherapy
    Jaeger, Ulrich
    ESMO OPEN, 2017, 2 (03)
  • [26] COST OF TREATMENT WITH BIOSIMILARS - CASE WITH RITUXIMAB IN ONCOHEMATOLOGY
    Boncheva, E.
    Cherneva, D.
    Benisheva, T.
    VALUE IN HEALTH, 2022, 25 (01) : S148 - S149
  • [27] COMPARISON OF EFFICACY AND SAFETY OF BIOSIMILAR RITUXIMAB AND ORIGINATOR RITUXIMAB IN REAL CLINICAL PRACTICE
    Kusevich, D.
    Olyunin, Y.
    Nasonov, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1131 - 1131
  • [28] DO CONTEXTUAL FACTORS INFLUENCE SURVIVAL ONDRUG OF BIOSIMILARS IN CLINICAL PRACTICE?
    Di Giuseppe, D.
    Frisell, T.
    Lindqvist, E.
    Jacobsson, L.
    Turesson, C.
    Sjowall, C.
    Askling, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 317 - 318
  • [29] Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
    Waller, Cornelius F.
    Moebius, Julia
    Fuentes-Alburo, Adolfo
    BRITISH JOURNAL OF CANCER, 2021, 124 (08) : 1346 - 1352
  • [30] Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma
    Coleman, Morton
    Lammers, Philip E.
    Ciceri, Fabio
    Jacobs, Ira A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (04): : 175 - 181
12345